Yesterday, the Sixth Circuit issued its decision in Fulgenzi v. PLIVA, Inc., a case involving a state law claim for failure to warn against a generic drug manufacturer. Case No. 12-3504 (6th Cir. March 13, 2013). The court held that a failure-to-warn claim could proceed against a generic manufacturer that had failed to timely follow the brand-name label, creating a narrow exception to the preemption defense established by PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011).
In Mensing¸ the Supreme Court held that failure-to-warn claims against generic drug manufacturers were preempted. The Court reasoned that, because federal law requires generic manufacturers to maintain the “same” labels as that of the branded drug, generic manufacturers cannot independently change their drugs’ labels.
Please see full alert below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Topics: Drug Manufacturers, Failure To Warn, FDCA, Generic Drugs, Labeling, PLIVA v Mensing, Preemption
Published In: Civil Procedure Updates, Products Liability Updates, Science, Computers & Technology Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Morrison & Foerster LLP | Attorney Advertising